Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

Hypertension Clinical Trial

— ACCOMPLISH  

Official title:

A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00170950
• Other study ID #: CCIB002I2301
• Status: Terminated
• Phase: Phase 3
• Start date: October 2003
• Est. completion date: May 2008

Study information

• Verified date: October 2023
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.

Other known NCT identifiers

• NCT00097864

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11506
• Est. completion date: May 2008
• Est. primary completion date: January 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• At least 55 years of age.

• Previously untreated or treated hypertension.

• For patients >= 60 years, evidence of at least one CV disease or target organ damage, or for patients 55-59 years evidence of at least two CV diseases or target organ damage from two different organ systems as defined in the protocol.

Exclusion Criteria:

• Allergy to any of the drugs administered in this trial.

• Current angina pectoris (ie, no anginal event requiring NTG within 1 month prior to Visit 1).

• Secondary hypertension.

• Refractory hypertension defined as SBP >= 180 mmHg and/or DBP >= 110 mmHg unresponsive to triple-drug regimens of sympatholytics, diuretics and vasodilators.

• History of symptomatic heart failure (NYHA classes II-IV) or ejection fraction < 40%.

• Myocardial infarction, coronary revascularization (CABG or PCI), unstable angina within one month of Visit 1.

• Stroke or transient ischemic event (TIA) within 3 months of Visit 1.

• Significant obstructive valvular cardiovascular disease or any valvular disease expected to lead to surgery during the course of the study.

• Evidence of hepatic disease (AST or ALT values >= 2 X upper limit of normal).

• Impaired renal function (serum creatinine >= 2.5 mg/dL (221 µmol/L)).

• Baseline serum potassium of > 5.2 meq/L not on potassium supplements.

• History of malignancy including leukemia and lymphoma (but not basal cell skin cancer) within the last 5 years.

• History of clinically significant auto immune disorders such as Systemic Lupus Erythematosus.

• Significant non-cardiovascular illness or condition likely to result in death prior to trial completion, e.g., major organ transplant (life expectancy <5 years).

• Significant cardiovascular disease such as an aortic aneurysm = 6 cm, likely requiring surgical intervention during the course of the study.

Other protocol-defined exclusion criteria applied to the study.

Related Conditions & MeSH terms

• Hypertension

Intervention

Drug:
• Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1
Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
• Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2
Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
• Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
• Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1
Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
• Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2
Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
• Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.

Locations

Country	Name	City	State
Denmark	sites in Denmark	Denmark
Finland	sites in Finland	Finland
Norway	sites in Norway	Norway
Sweden	sites in Sweden	Sweden
United States	Novartis Pharmaceuticals	East Hanover	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Novartis

Countries where clinical trial is conducted

United States,  Denmark,  Finland,  Norway,  Sweden, 

References & Publications (1)

Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 4;359(23) — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event	CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes.	For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
Secondary	Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event	Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG).	For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
Secondary	Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke	CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes.	For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])